MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$7,200,623
Net Income
$2,773,163
Net Profit Margin
38.51%
EPS
$0.09
Unit: Dollar
Revenue Breakdown
United States Sales
North And South America Sales Ex...
Other International Sales
Revenue Breakdown
Syringes
Easy Point Needles
Blood Collection Products
Other Products
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Sales, net
7,200,623
7,177,397
10,085,723
10,445,733
Product
6,351,053
7,358,809
7,572,544
9,721,614
Royalty
658,718
656,996
827,275
831,209
Total cost of sales
7,009,771
8,015,805
8,399,819
10,552,823
Gross profit (loss)
190,852
-838,408
1,685,904
-107,090
Sales and marketing
1,534,739
1,734,070
1,583,760
1,661,743
Research and development
187,291
170,416
199,462
160,049
General and administrative
3,614,724
3,425,024
3,556,724
3,201,955
Total operating expenses
5,336,754
5,329,510
5,339,946
5,023,747
Loss from operations
-5,145,902
-6,167,918
-3,654,042
-5,130,837
Litigation proceeds
-
-
-
1,900,000
Other income - tia
1,468,734
1,477,730
1,516,268
1,471,235
Unrealized gain (loss) on debt and equity securities
-179,147
192,172
2,383,779
1,555,676
Loss on trading debt securities
-
-
-343
-
Gain on trading debt and equity securities
6,366,467
-
-
-
Interest and other income
341,164
295,124
147,663
140,526
Interest expense
18,705
20,441
20,585
22,257
Net income (loss) before income taxes
2,832,611
-4,223,333
372,740
-85,657
Provision for income taxes
1,837
1,837
1,693
1,814
Net income (loss)
2,830,774
-4,225,170
371,047
-87,471
Preferred stock dividend requirements
57,611
57,611
57,611
57,611
Net income (loss) applicable to common shareholders
2,773,163
-4,282,781
313,436
-145,082
Basic EPS
0.09
-0.14
0.01
0
Diluted EPS
0.09
-0.14
0.01
0
Basic Average Shares
29,937,159
29,937,159
29,937,159
29,937,159
Diluted Average Shares
29,937,159
29,937,159
29,937,159
29,937,159
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Syringes
$5,299,242
(-10.61%↓ Y/Y)
Blood Collection
Products
$294,940
(-2.59%↓ Y/Y)
Easy Point Needles
$272,174
(-93.51%↓ Y/Y)
Other Products
$7,164
(-62.55%↓ Y/Y)
Syringes
$829,832
(-86.00%↓ Y/Y)
Easy Point Needles
$347,092
(-91.73%↓ Y/Y)
Syringes
$121,478
(-97.95%↓ Y/Y)
Easy Point Needles
$27,152
(-99.35%↓ Y/Y)
Blood Collection
Products
$1,000
(-99.67%↓ Y/Y)
Other Products
$549
(-97.13%↓ Y/Y)
United States Sales
$5,873,520
North And South
America Sales Excluding...
$1,176,924
Other International
Sales
$150,179
Gain on trading debt
and equity...
$6,366,467
Other income - tia
$1,468,734
(-0.17%↓ Y/Y)
Interest and other income
$341,164
(142.78%↑ Y/Y)
Sales, net
$7,200,623
(-31.07%↓ Y/Y)
Net income (loss)
before income taxes
$2,832,611
(3406.92%↑ Y/Y)
Loss from operations
-$5,145,902
(-0.29%↓ Y/Y)
Gross profit (loss)
$190,852
(278.22%↑ Y/Y)
Unrealized gain (loss) on
debt and equity...
-$179,147
(-111.52%↓ Y/Y)
Interest expense
$18,705
(-15.96%↓ Y/Y)
Total cost of sales
$7,009,771
(-33.57%↓ Y/Y)
Net income (loss)
$2,830,774
(3336.24%↑ Y/Y)
Provision for income taxes
$1,837
(1.27%↑ Y/Y)
Total operating
expenses
$5,336,754
(6.23%↑ Y/Y)
Product
$6,351,053
(-34.67%↓ Y/Y)
Royalty
$658,718
(-20.75%↓ Y/Y)
Net income (loss)
applicable to common...
$2,773,163
(2011.45%↑ Y/Y)
Preferred stock dividend
requirements
$57,611
(0.00%↑ Y/Y)
General and
administrative
$3,614,724
(12.89%↑ Y/Y)
Sales and marketing
$1,534,739
(-7.64%↓ Y/Y)
Research and development
$187,291
(17.02%↑ Y/Y)
Buy us a coffee
RETRACTABLE TECHNOLOGIES INC (RVP)
RETRACTABLE TECHNOLOGIES INC (RVP)